United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Specialty pharmacy profit pools are still growing ... running tests on a biotechnology product. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company specializing in treatments ...

United Therapeutics Corporation (NASDAQ ... and again what is normally a seasonally weak fourth quarter for specialty pharmacy ordering. In the fourth quarter, we saw record patient shipments ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $6.19 per share, missing estimates of $6. ...